Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 21, 2018 12:58 ET | Source: CROSSJECT

CROSSJECT : point d'activité - novembre 2018

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Communiqué de Presse Point d'activité...
November 09, 2018 16:46 ET | Source: Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Announces Third Quarter 2018 Financial Results and Business Update

SAN DIEGO, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter ended September 30, 2018 and a business update....
November 08, 2018 16:10 ET | Source: Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2018

Reports Net Revenues of $75.5 Million for the Three Months Ended September 30, 2018 RANCHO CUCAMONGA, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)...
November 08, 2018 16:05 ET | Source: BioDelivery Sciences International, Inc.

BioDelivery Sciences Reports Strong Third Quarter 2018 Financial Results

BELBUCA® continued on an accelerated growth trajectory, with revenue increasing 92% YOY and 27% versus prior quarterBELBUCA total prescriptions experienced its largest quarter over quarter increase...
November 07, 2018 21:55 ET | Source: Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc. Announces Reintroduction of Primatene® MIST

Primatene® MIST fills unmet medical need as the only FDA approved over-the-counter asthma inhaler RANCHO CUCAMONGA, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc.,...
November 07, 2018 16:05 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc. Reports Third Quarter 2018 Financial Results and Provides Corporate Update

SANTA MONICA, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
November 05, 2018 16:15 ET | Source: INSYS Therapeutics, Inc.

INSYS Therapeutics to Assess Strategic Alternatives for Opioid-Related Assets

Company Reiterates Focus on Pharmaceutical Cannabinoids and Spray Technology PHOENIX, Nov. 05, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development,...
November 05, 2018 08:00 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Announces Last Patient, Last Visit in Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa

Top-line Results Expected in First Quarter of 2019 SANTA MONICA, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT), a specialty pharmaceutical company developing...
November 01, 2018 16:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months of 2018

Q3 2018 performance in line with guidanceRevises full year 2018 financial forecast to reflect anticipated strong full year organic business performance, expected at the higher end of the previous...
November 01, 2018 16:10 ET | Source: BioDelivery Sciences International, Inc.

BioDelivery Sciences Announces Further Significant Expanded Preferred Coverage For BELBUCA®

More than 100 million Covered Lives Now Have Preferred Access to BELBUCA RALEIGH, N.C., Nov. 01, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly...